PFE heads into its October 27 earnings date with a cluster of insider buying at the top, options traders turning less defensive, and short sellers with no meaningful conviction either way.
The insider angle is the standout this week. Chief Executive Albert Bourla spent just over $1 million buying 38,000 shares in the open market on August 12, paying around $26.34 a share. Two independent directors bought on the same date in early August: Ronald Blaylock picked up 39,231 shares for roughly $999,000, and Mortimer Buckley bought 37,632 shares for around $960,000. None of these purchases were under a pre-arranged 10b5-1 plan, which makes them discretionary buys. Combined, the 90-day net insider position is positive at 111,585 shares worth approximately $2.9 million. The only selling came from SVP and Controller Jennifer DaMico in two small transactions, both well under $85,000 in total. The pattern is three senior buyers near the same price point, all without a plan, in a stock that had recently traded near multi-year lows.
Options positioning has shifted in a direction that corroborates the insider tone. The put/call ratio closed at 0.72 on Tuesday, meaningfully below its 20-day average of 0.76 and about 1.6 standard deviations below that mean. That is close to the most call-heavy reading of the past year, the 52-week low sits at 0.64. For most of August and into early September, PCR was running above 0.80, reflecting heavier demand for downside protection. That has unwound over the past two weeks. Whether the shift reflects fresh call buying ahead of October earnings or simply put decay, the directional lean in options is now the opposite of where it was a month ago.
Short positioning offers little in the way of drama. Short interest is low at 2.7% of the free float, and has drifted only fractionally higher over the month, up about 1% in aggregate. The lending market is entirely untaxed. Shares available to borrow relative to shorts are effectively unlimited, with 5.4 billion shares available against 151 million short, and cost to borrow is a negligible 0.37%. The ORTEX short score has ticked up to 35.3, its highest reading of the past two weeks, but the absolute level is modest and has barely moved. There is no squeeze pressure, no borrow scarcity, and no sign of a significant short build.
The Street is broadly neutral but not hostile. Most recent analyst activity from the July to September window shows a pattern of maintained ratings alongside lower price targets. JPMorgan's Chris Schott cut his target to $28 from $30 in early July while keeping a Neutral rating. BofA trimmed to $26. HSBC moved in the opposite direction in September, raising to $30 after downgrading to Hold in July. The consensus mean target is $28.88, barely above the current price of $28.72, which frames the Street's view as "fairly valued here" rather than a clear buy or sell. Bulls point to around $60 billion in annual sales anchored by Prevnar, Ibrance, and Eliquis, plus a forward earnings trajectory that ranks in the 88th percentile for year-on-year improvement. Bears flag rising gross-to-net headwinds on premium products like Vyndaqel and Ibrance that could make near-term revenue recognition lumpy. The dividend score ranks in the 94th percentile, reflecting a yield that has historically been one of the stock's key support mechanisms, though the most recent dividend data in this snapshot is from 2022 and should be verified independently before being relied upon.
Alt data adds modest context. Medicaid units reimbursed for Pfizer drugs were down 17% against Q1 last year, and Medicaid prescriptions fell 21% over the same period. These are government reimbursement channel figures, not a measure of total sales, but the volume decline is notable. No alt data series has been measured to lead Pfizer's reported revenue figures, so these readings are colour rather than forward signal.
The most recent earnings print, reported in early August, produced a one-day gain of 3.1% and a five-day gain of 6.4%, the better of the two recent history data points. Norges Bank was the one significant institutional seller last reported, trimming by 7.2 million shares, while BlackRock added 31 million shares and now holds 9.3% of the company. Among correlated peers, BMY added roughly 1% on the week while SIGA and AMPH both rose more than 5%, so PFE's 2.8% weekly gain sits comfortably in the pack.
The October 27 print is the next hard catalyst, and the gap between the Street's consensus target and current price makes the revenue and gross-to-net commentary around Vyndaqel and Ibrance the most watched line items in that release.
See the live data behind this article on ORTEX.
Open PFE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
